Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Rafael G. Amado, Michael Wolf, Marc Peeters et al. · Journal of Clinical Oncology · 2008
PURPOSE: Panitumumab, a fully human antibody against the epidermal growth factor receptor (EGFR), has activity in a subset of patients with metastatic colorectal cancer (mCRC). Although activating mutations in KRAS, a small G-protein downstream of EGFR, correlate with poor response to anti-EGFR antibodies in mCRC, their role as a selection marker has not been established in randomized trials. PATIENTS AND METHODS: KRAS mutations were detected using polymerase chain reaction on DNA from tumor sections collected in a phase III mCRC trial comparing panitumumab monotherapy to best supportive care (BSC). We tested whether the effect of panitumumab on progression-free survival (PFS) differed by KRAS status. RESULTS: KRAS status was ascertained in 427 (92%) of 463 patients (208 panitumumab, 219 BSC). KRAS mutations were found in 43% of patients. The treatment effect on PFS in the wild-type (WT) KRAS group (hazard ratio [HR], 0.45; 95% CI: 0.34 to 0.59) was significantly greater (P < .0001) than in the mutant group (HR, 0.99; 95% CI, 0.73 to 1.36). Median PFS in the WT KRAS group was 12.3 weeks for panitumumab and 7.3 weeks for BSC. Response rates to panitumumab were 17% and 0%, for the WT and mutant groups, respectively. WT KRAS patients had longer overall survival (HR, 0.67; 95% CI, 0.55 to 0.82; treatment arms combined). Consistent with longer exposure, more grade III treatment-related toxicities occurred in the WT KRAS group. No significant differences in toxicity were observed between the WT KRAS group and the overall population. CONCLUSION: Panitumumab monotherapy efficacy in mCRC is confined to patients with WT KRAS tumors. KRAS status should be considered in selecting patients with mCRC as candidates for panitumumab monotherapy.
Cited by 3,208 works. doi:10.1200/jco.2007.14.7116 Open-access PDF
Authors
- Rafael G. Amado
- Marc Peeters
- Eric Van Cutsem
- Salvatore Siena
- Daniel J. Freeman
- Todd Juan
- Robert S. Sikorski
- Sid Suggs
- Robert Radinsky
- Scott Donald Patterson
- David D. Chang
References
- Mutations of the BRAF gene in human cancer
- Genetic Alterations during Colorectal-Tumor Development
- Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
- ras oncogenes in human cancer: a review.
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
- Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS)
- Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
- Testing for Qualitative Interactions between Treatment Effects and Patient Subsets
- KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
- KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer